Monoclonal Antibodies (mAbs) Approved for Cancer Treatment in the 2020s

Simple item page
AuthorPouya Safarzadeh Kozanien
AuthorAbdolhossein Naserien
AuthorPooria Safarzadeh Kozanien
AuthorSanaz Khatamien
AuthorAbdolkarim Sheikhien
OrcidPouya Safarzadeh Kozani [0000-0002-2602-3871]en
OrcidPooria Safarzadeh Kozani [0000-0002-9901-7851]en
OrcidAbdolkarim Sheikhi [0000-0002-3559-5548]en
Issued Date2021-05-31en
AbstractMonoclonal antibodies are one of the most eminent types of immunotherapeutics that have taken over the biopharmaceutical market because they are approved for a wide range of cancers, either blood-based malignancies or solid tumors, and also non-cancer indications, from migraine to viral infections. Due to their wide applicability as immunotherapeutics, countless biopharmaceutical companies try to be in the competition by developing monoclonal antibodies and advancing into clinical trials with them. Since the approval of the first monoclonal antibodies, the speed of their discovery and approval for medical use have been rather incremental, so that the progress of this market has been anticipated to increase in the current decade. Herein, we take a look at some of the monoclonal antibodies, which have been approved for clinical use in the current decade, so far. Moreover, we underline the encouraging results from the clinical trials that led to the approval of these immunotherapeutics.en
DOIhttps://doi.org/10.5812/tms.116686en
URIhttps://brieflands.com/journals/jai/articles/116686en
KeywordCancer Immunotherapyen
KeywordMonoclonal Antibodiesen
KeywordAntibody-Drug Conjugatesen
KeywordSolid Tumorsen
KeywordHematologic Malignanciesen
PublisherBrieflandsen
TitleMonoclonal Antibodies (mAbs) Approved for Cancer Treatment in the 2020sen
TypeReview Articleen

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
tms-1-2-116686.pdf
Size:
125.75 KB
Format:
Adobe Portable Document Format
Description:
Article/s PDF
Download

Collections

Trends in Medical Sciences